Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage (PITCH-ER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01960153
Recruitment Status : Withdrawn (Award was ended by NIH for parent study)
First Posted : October 10, 2013
Last Update Posted : September 12, 2017
National Heart, Lung, and Blood Institute (NHLBI)
New England Research Institutes
Information provided by (Responsible Party):
Ravi Thadhani, Massachusetts General Hospital

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
  Recruitment Status : Withdrawn
  Estimated Primary Completion Date : December 2017
  Estimated Study Completion Date : May 2018